NLRP3 and neoplasm: PD-1 blockade leads to CD8+ T cell activation and NLRP3 inflammasome activation, which results in the integration of granulocytic myeloid-derived suppressor cells (PMN-MDSCs) into tumors, and, ultimately, a tumor-permissive environment [15,16].